Kissei And Takeda Receive Approval For Rapid-Acting Insulin Secretagogue Glufast In Japan
This article was originally published in PharmAsia News
Executive Summary
Kissei and Takeda obtained approval for their jointly marketed rapid-acting insulin secretagogue Glufast tablets (mitiglinide) for the treatment of type 2 diabetes in Japan Sept. 13.